About EMMC

About EMMC
J. Joseph Prendergast
Contact EMMC
Dr. Joe's Book
Link With Us

Press Corner

Improvement of Sensory Impairment in Patients with Peripheral Neuropathy


Objective:  Twenty-seven patients, including 21 with lower-extremity sensory impairment associated with diabetic peripheral neuropathy (DPN) and 6 with other etiologies, received treatment with monochromatic near infrared photo energy (890 nm), delivered by the Anodyne Therapy System (ATS) to determine the extent of reduction of sensory impairment in myelinated and unmyelinated sensory fibers of theperoneal nerve.

Methods:  All patients exhibited abnormal sensation based on a qualifying examination (baseline CPT) with the Neurometer CPT (current perception threshold).  The patients received 10 treatments with the ATS over 2 weeks and then were retested with the Neurometer.

Results:  All patients obtained reduction in sensory impairment compared to baseline CPT measures, and 16 of 27 patients achieved normal sensation.  Ten of these patients had been tested previously (initial CPT) and did not exhibit spontaneous reduction in sensory impairment during the average of 27 months prior to baseline CPT with the Neurometer CPT.  However, after receivign ATS treatments, all improved compared to both initial CPT results and baseline CPT.

Conclusion:  Based on these data, ATS appears to be a safe and effective treatment to reduce sensory impairment associated with peripheral neuropathy due to diabetes and other causes.


Page 321 

Dr. Joe's Book | E-News | 2001-2007 EMMC | HIPAA | Terms of Use/Disclaimer | Privacy Policy | Back to Top
Contact EMMC | Endocrine Metabolic Medical Center, Tel.: (650) 566-9810  Fax: (650) 566-9825